Japanese cedar pollinosis
Conditions
Interventions
A multicenter, randomized, double-blind, placebo-controlled, parallel-group, study.
Jabara group: Jabara powder ( 5g/pack ) twice
a day. for 4weeks.
placebo group: placebo powder ( 5g/pack ) twice a
Jabara powder
Sponsors
Otani Yoshio
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with three main symptoms of sneezing, rhinorrhea and nasal obstruction, during Japanese cedar pollen dispersal season inthe past two consective years and with positive IgE titer for Japanese cedar pollen 2) Patients aged from 20 to 74 years old when the informed consent form were gotten 3) Patients who wrote informed consent form by their free will, After receiving a sufficient explanation and fully understanding 4) Outpatients 5) Patients who can describe Hay fever Google form questionnaire (distribute the paper questionnaire form if the internet is not available) and QOL questionnaire
Exclusion criteria
Exclusion criteria: 1) Patients receiving allergen (Japanese cedar pollen) immunotherapy or those who will receive allergen immunotherapy during the study 2) Patients who want laser therapy. 3) Patients undergoing anti-IgE antibody therapy and patients who want the therapy. 4) Patients who were suspected infectious disease within four weeks prior to enrollment. 5) Patients who were suspected acute rhinitis or chronic and acute sinusitis which are similar to allergic rhinitis. 6) Patients in need of steroid oral medication, 7) Patients who were taken oral steroid therapy within four weeks prior to enrollment. 8) Patients who have taken Kitayamamura Jabara products within four weeks prior to enrollment. And patients who have taken Jabara powder. 9) Patients allergic to citrus or sweet potato. 10) Pregnant patients or patients with a possibility of pregnancy. 11) Patients during breast feeding 12) Patients who join other clinical trials or clinical research when they are registered. Patients who had taken the other clinical trial drug or clinical research drug within three months prior to enrollment. 13) Patients the principal investigator or other investigator determines to be inadequate in order to safely implement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| JRQLQ No.1 | — |
Secondary
| Measure | Time frame |
|---|---|
| TNSS (total nasal symptom score) TOSS (total ocular symptom score) TNOSS (total nasal ocular symptom score) TNMS (total nasal medication score) TOMS (total ocular medication score) TNOSMS (total nasal ocular symptom medication score) nasal peak expiratory flow nasal resistance nasal nitric oxide concentration | — |
Contacts
Public ContactYoshio Otani
Ikebukuro Otani Clinic
Outcome results
None listed